Copyright
©The Author(s) 2019.
World J Gastroenterol. Oct 14, 2019; 25(38): 5883-5896
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5883
Published online Oct 14, 2019. doi: 10.3748/wjg.v25.i38.5883
Table 1 Demographic and clinical features of patients
| Demographic data | Value |
| Male/female | 16/15 |
| Caucasian/sub-Saharan/chinese1 | 22/8/1 |
| Age (years: mean ± SD) | 45.1 ± 10.2 |
| Virological data | |
| HBV-DNA positivity (persistent/fluctuant)2 | 28/3 |
| HBV-DNA titters (IU/mL: Mean ± SD)3 | 1.4 × 103 ± 3.5 × 104 |
| Clinical data4 | |
| Persistently normal/marginally altered AST or ALT | 18/13 |
| Persistently normal/marginally altered AST | 25/6 |
| Persistently normal/marginally altered ALT | 20/11 |
| AST (IU/L: mean ± SD) | 25.6 ± 9.5 |
| ALT (IU/L: mean ± SD) | 28.5 ± 14.3 |
| Fibrosis stage (Fibroscan) | |
| F0-F1 | 22 |
| F2 | 6 |
| Not available | 3 |
Table 2 Assignment of risk of hepatocellular carcinoma development associated to each hepatitis B virus genetic variants
| HCC risk | HBV region | Genetic variant |
| High | ||
| PreS2 | PreS2 deletions | |
| BCP | C1653T, T1753V (A/C/G), A1762T + G1764A | |
| Precore | G1896A, G1899A | |
| Suspect | ||
| PreS1 | PreS1 deletions | |
| PreS2 | T53C | |
| BCP | C1773T | |
| Precore | A1846T | |
| Core | C1914G, C2289A | |
| Minor | ||
| PreS1 | T3098C, T3139A | |
| PreS2 | PreS2 start codon | |
| S | T766A, T791A | |
| BCP | T1674C, G1727, C1741, C1761, C1766T, T1768A | |
| Precore | C1858T, G1862T | |
| Core | C1909, A1934T, C2002T, T2003A, C2100A, A2159G, A2189C, A2246C | |
- Citation: Gil-García AI, Madejón A, Francisco-Recuero I, López-López A, Villafranca E, Romero M, García A, Olveira A, Mena R, Larrubia JR, García-Samaniego J. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment. World J Gastroenterol 2019; 25(38): 5883-5896
- URL: https://www.wjgnet.com/1007-9327/full/v25/i38/5883.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i38.5883
